Salama, L., Saleh, H., Abdel-Rhman, S., Barwa, R., Hassan, R. (2021). Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.. test, 5(Pharmacognosy-Microbiology), 89-99. doi: 10.21608/rpbs.2021.81598.1107
Lamiaa Adel Salama; Hazem Saleh; Shaymaa Abdel-Rhman; Rasha Barwa; Ramadan Hassan. "Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.". test, 5, Pharmacognosy-Microbiology, 2021, 89-99. doi: 10.21608/rpbs.2021.81598.1107
Salama, L., Saleh, H., Abdel-Rhman, S., Barwa, R., Hassan, R. (2021). 'Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.', test, 5(Pharmacognosy-Microbiology), pp. 89-99. doi: 10.21608/rpbs.2021.81598.1107
Salama, L., Saleh, H., Abdel-Rhman, S., Barwa, R., Hassan, R. Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.. test, 2021; 5(Pharmacognosy-Microbiology): 89-99. doi: 10.21608/rpbs.2021.81598.1107

Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.

Records of Pharmaceutical and Biomedical Sciences
Article 10, Volume 5, Pharmacognosy-Microbiology - Serial Number 2, January 2021, Pages 89-99    PDF (542.44 K)
Document Type: Original Article
DOI: 10.21608/rpbs.2021.81598.1107
Authors
Lamiaa Adel Salama* 1; Hazem Saleh2; Shaymaa Abdel-Rhman3; Rasha Barwa3; Ramadan Hassan3
1Microbiology and Immunology Department, Faculty of pharmacy, Horus university, New Damietta 34518, Egypt.
2Urology and Nephrology center, Mansoura University.
3Microbiology and Immunology Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Abstract
Background: The Extended spectrum β-lactamases (ESBLs) production is one of the most essential mechanism of drug resistance in Proteus mirabilis (P. mirabilis). Objective: Phenotypic and genotypic detection of extended spectrum β -lactamases production in P. mirabilis and its antimicrobial resistance among clinical isolates. Methods: A total of Sixty P. mirabilis clinical isolates were tested for Extended spectrum β lactamase production by modified double disc synergy test (MDDST). Polymerase chain reaction (PCR) was done to detect Extended spectrum β-lactamases genes in the clinical isolates. Antimicrobial susceptibility testing was done by means of Kirby Bauer disc diffusion method. Results: Out of the 60 P. mirabilis clinical isolates, 17 isolates (28.33%) were ESBL producers by phenotypic test. Genotypically; ESBLs genes were detected and the most prevalent ESBL resistance gene was TEM (91.7%) followed by SHV (75%), CTX-2-59 (56.7%) and CtxM-15 (51.7%). Moderate level of resistance to ofloxacin, ciprofloxacin, amoxicillin/ clavulanic acid, cefotaxime and ceftazidime (60.0%, 58.3%, 45.0%, 41.7% and 40.0% respectively) was recorded. In addition, 73.33% of isolates were classified as multidrug resistant (MDR). Conclusion: Monitoring of Extended spectrum β-lactamase producing P. mirabilis is very important because of its high prevalence among urinary tract infections. Also; increasing awareness for clinicians and enhancing laboratories 
Keywords
P. miribilis; Extended spectrum β lactamase; antimicrobial resistance; urinary tract infections
Statistics
Article View: 380
PDF Download: 350